This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Promising Trial for Bristol-Myers, Pfizer Drug

NEW YORK ( TheStreet) -- Bristol-Myers Squibb (BMY - Get Report) and Pfizer's (PFE - Get Report) apixaban drug showed promise in preventing strokes in a clinical study, the companies said Sunday.

In a Phase 3 trial, the drug, which has the commercial name ELIQUIS, was compared with another drug, warfarin, in 18,201 patients with atrial fibrillation and at least one risk factor for stroke.

Compared with warfarin, apixaban reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31% and mortality by 11%, the companies said.

The companies are developing the drug to prevent and treat blood clots.

"The risk for stroke in patients with atrial fibrillation is a major public health concern in an aging population," Dr. Christopher B. Granger, a professor of medicine at Duke University Medical Center and lead investigator of the study, was quoted saying in a news release from Bristol-Myers and Pfizer.

> > Bull or Bear? Vote in Our Poll

"We are therefore encouraged by the outcome of the ARISTOTLE trial, which showed that apixaban, as compared with warfarin, significantly reduced the risk of stroke or systemic embolism, major bleeding, and mortality," Granger said.

The clinical trial results were presented at a medical conference in Paris and published in The New England Journal of Medicine.

Shares of Bristol-Myers Squibb closed Friday up 24 cents at $28.72, while shares of Pfizer ended the session up 25 cents at $18.21.
This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $72.26 2.89%
PFE $32.91 -0.27%
AAPL $95.03 -2.90%
FB $116.73 7.20%
GOOG $691.02 -2.10%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs